1. A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors. Issue 1 (December 2016) Authors: Haense, N.; Atmaca, A.; Pauligk, C.; Steinmetz, K.; Marmé, F.; Haag, G.; Rieger, M.; Ottmann, O.; Ruf, P.; Lindhofer, H.; Al-Batran, S.-E. Journal: BMC cancer Issue: Volume 16:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗